Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 26 May 2006:
Vol. 312. no. 5777, pp. 1175 - 1178
DOI: 10.1126/science.1125951
Prev | Table of Contents | Next

Perspective

Targeting Tyrosine Kinases in Cancer: The Second Wave

Jose Baselga

One of the most exciting developments in cancer research in recent years has been the clinical validation of molecularly targeted drugs that inhibit the action of pathogenic tyrosine kinases. Treatment of appropriately selected patients with these drugs can alter the natural history of their disease and improve survival. The clinical validation of these "first-generation" tyrosine kinase inhibitors has been the prelude to a second wave of advances in molecular targeting that is expected to further change the way we classify and treat cancer. Efforts are now being directed at identifying the tumor subtypes and patients who will benefit the most from these drugs. In addition, new compounds that circumvent acquired resistance to the first-generation tyrosine kinase inhibitors are being tested in patients with refractory disease. Agents directed against new molecular targets are also being explored.

Oncology Program, Vall d'Hebron University Hospital and Vall d'Hebron Research Institute, Universidad Autónoma de Barcelona, Barcelona 08035, Spain.

E-mail: jbaselga{at}vhebron.net

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Apratoxin A Reversibly Inhibits the Secretory Pathway by Preventing Cotranslational Translocation.
Y. Liu, B. K. Law, and H. Luesch (2009)
Mol. Pharmacol. 76, 91-104
   Abstract »    Full Text »    PDF »
Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy.
H. Jarvelainen, A. Sainio, M. Koulu, T. N. Wight, and R. Penttinen (2009)
Pharmacol. Rev. 61, 198-223
   Abstract »    Full Text »    PDF »
The Effect of Combination Anti-Endothelial Growth Factor Receptor and Anti-Vascular Endothelial Growth Factor Receptor 2 Targeted Therapy on Lymph Node Metastasis: A Study in an Orthotopic Nude Mouse Model of Squamous Cell Carcinoma of the Oral Tongue.
D. Sano, S. Choi, Z. L. Milas, G. Zhou, C. E. Galer, Y.-W. Su, M. Gule, M. Zhao, Z. Zhu, and J. N. Myers (2009)
Arch Otolaryngol Head Neck Surg 135, 411-420
   Abstract »    Full Text »    PDF »
Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectories.
S. Yang, N. K. Banavali, and B. Roux (2009)
PNAS 106, 3776-3781
   Abstract »    Full Text »    PDF »
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.
F. Carlomagno, T. Guida, S. Anaganti, L. Provitera, S. Kjaer, N. Q McDonald, A. J Ryan, and M. Santoro (2009)
Endocr. Relat. Cancer 16, 233-241
   Abstract »    Full Text »    PDF »
High-Throughput Biochemical Kinase Selectivity Assays: Panel Development and Screening Applications.
A. Card, C. Caldwell, H. Min, B. Lokchander, Hualin Xi, S. Sciabola, A. V. Kamath, S. L. Clugston, W. R. Tschantz, Leyu Wang, et al. (2009)
J Biomol Screen 14, 31-42
   Abstract »    PDF »
Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors.
P. Ross-Macdonald, H. de Silva, Q. Guo, H. Xiao, C.-Y. Hung, B. Penhallow, J. Markwalder, L. He, R. M. Attar, T.-a. Lin, et al. (2008)
Mol. Cancer Ther. 7, 3490-3498
   Abstract »    Full Text »    PDF »
N-Glycans in cancer progression.
K. S Lau and J. W Dennis (2008)
Glycobiology 18, 750-760
   Abstract »    Full Text »    PDF »
Perspectives for Improved and More Accurate Classification of Thyroid Epithelial Tumors.
M. Eszlinger, K. Krohn, S. Hauptmann, H. Dralle, T. J. Giordano, and R. Paschke (2008)
J. Clin. Endocrinol. Metab. 93, 3286-3294
   Abstract »    Full Text »    PDF »
Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies.
M. Dechant, W. Weisner, S. Berger, M. Peipp, T. Beyer, T. Schneider-Merck, J. J. Lammerts van Bueren, W. K. Bleeker, P. W.H.I. Parren, J. G.J. van de Winkel, et al. (2008)
Cancer Res. 68, 4998-5003
   Abstract »    Full Text »    PDF »
Eight-channel iTRAQ Enables Comparison of the Activity of Six Leukemogenic Tyrosine Kinases.
A. Pierce, R. D. Unwin, C. A. Evans, S. Griffiths, L. Carney, L. Zhang, E. Jaworska, C.-F. Lee, D. Blinco, M. J. Okoniewski, et al. (2008)
Mol. Cell. Proteomics 7, 853-863
   Abstract »    Full Text »    PDF »
An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors.
P. Accornero, G. Lattanzio, T. Mangano, R. Chiarle, R. Taulli, F. Bersani, P. E. Forni, S. Miretti, C. Scuoppo, W. Dastru, et al. (2008)
Clin. Cancer Res. 14, 2220-2226
   Abstract »    Full Text »    PDF »
Prediction of Cancer Driver Mutations in Protein Kinases.
A. Torkamani and N. J. Schork (2008)
Cancer Res. 68, 1675-1682
   Abstract »    Full Text »    PDF »
From the Cover: Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
J. Tsai, J. T. Lee, W. Wang, J. Zhang, H. Cho, S. Mamo, R. Bremer, S. Gillette, J. Kong, N. K. Haass, et al. (2008)
PNAS 105, 3041-3046
   Abstract »    Full Text »    PDF »
Imaging Epidermal Growth Factor Receptor Expression In vivo: Pharmacokinetic and Biodistribution Characterization of a Bioconjugated Quantum Dot Nanoprobe.
P. Diagaradjane, J. M. Orenstein-Cardona, N. E. Colon-Casasnovas, A. Deorukhkar, S. Shentu, N. Kuno, D. L. Schwartz, J. G. Gelovani, and S. Krishnan (2008)
Clin. Cancer Res. 14, 731-741
   Abstract »    Full Text »    PDF »
Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib.
T. M. Gilmer, L. Cable, K. Alligood, D. Rusnak, G. Spehar, K. T. Gallagher, E. Woldu, H. L. Carter, A. T. Truesdale, L. Shewchuk, et al. (2008)
Cancer Res. 68, 571-579
   Abstract »    Full Text »    PDF »
Reinduction of ErbB2 in astrocytes promotes radial glial progenitor identity in adult cerebral cortex.
H.T. Ghashghaei, J. M. Weimer, R. S. Schmid, Y. Yokota, K. D. McCarthy, B. Popko, and E.S. Anton (2007)
Genes & Dev. 21, 3258-3271
   Abstract »    Full Text »    PDF »
Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244.
D. W. Ball, N. Jin, D. M. Rosen, A. Dackiw, D. Sidransky, M. Xing, and B. D. Nelkin (2007)
J. Clin. Endocrinol. Metab. 92, 4712-4718
   Abstract »    Full Text »    PDF »
In Situ Detection of Phosphorylated Platelet-derived Growth Factor Receptor {beta} Using a Generalized Proximity Ligation Method.
M. Jarvius, J. Paulsson, I. Weibrecht, K.-J. Leuchowius, A.-C. Andersson, C. Wahlby, M. Gullberg, J. Botling, T. Sjoblom, B. Markova, et al. (2007)
Mol. Cell. Proteomics 6, 1500-1509
   Abstract »    Full Text »    PDF »
Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF.
S. C. Kiley and R. L. Chevalier (2007)
Am J Physiol Renal Physiol 293, F895-F903
   Abstract »    Full Text »    PDF »
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.
C. Peng, J. Brain, Y. Hu, A. Goodrich, L. Kong, D. Grayzel, R. Pak, M. Read, and S. Li (2007)
Blood 110, 678-685
   Abstract »    Full Text »    PDF »
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas.
M. V. Karamouzis, J. R. Grandis, and A. Argiris (2007)
JAMA 298, 70-82
   Abstract »    Full Text »    PDF »
s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis.
J. Li, R. Berbeco, R. J. Distel, P. A. Janne, L. Wang, and G. M. Makrigiorgos (2007)
Nucleic Acids Res. 35, e84
   Abstract »    Full Text »    PDF »
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms.
H. Y. Zou, Q. Li, J. H. Lee, M. E. Arango, S. R. McDonnell, S. Yamazaki, T. B. Koudriakova, G. Alton, J. J. Cui, P.-P. Kung, et al. (2007)
Cancer Res. 67, 4408-4417
   Abstract »    Full Text »    PDF »
Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer.
M. Scaltriti, F. Rojo, A. Ocana, J. Anido, M. Guzman, J. Cortes, S. Di Cosimo, X. Matias-Guiu, S. Ramon y Cajal, J. Arribas, et al. (2007)
J Natl Cancer Inst 99, 628-638
   Abstract »    Full Text »    PDF »
A Selective Small Molecule Inhibitor of c-Met, PHA665752, Inhibits Tumorigenicity and Angiogenesis in Mouse Lung Cancer Xenografts.
N. Puri, A. Khramtsov, S. Ahmed, V. Nallasura, J. T. Hetzel, R. Jagadeeswaran, G. Karczmar, and R. Salgia (2007)
Cancer Res. 67, 3529-3534
   Abstract »    Full Text »    PDF »
Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non-Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor.
P. Steiner, C. Joynes, R. Bassi, S. Wang, J. R. Tonra, Y. R. Hadari, and D. J. Hicklin (2007)
Clin. Cancer Res. 13, 1540-1551
   Abstract »    Full Text »    PDF »
PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors.
I. K. Mellinghoff, T. F. Cloughesy, and P. S. Mischel (2007)
Clin. Cancer Res. 13, 378-381
   Abstract »    Full Text »    PDF »
Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b.
G. K. Scott, A. Goga, D. Bhaumik, C. E. Berger, C. S. Sullivan, and C. C. Benz (2007)
J. Biol. Chem. 282, 1479-1486
   Abstract »    Full Text »    PDF »
Stimulatory autoantibodies to the PDGF receptor in scleroderma..
H. Okamoto, E. Lozano, M. Segarra, M. C. Cid, A. Gabrielli, S. S. Baroni, E. V. Avvedimento, and F. K. Tan (2006)
N. Engl. J. Med. 355, 1278
   Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)